Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 3/20 | 0.44 |
| ▸ | CTSK | P43235 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.37 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 3/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.33 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20601602 | 0.81 | GRM5 (0.41) | GRM5ATMCYP2A6BACE1KCNH2 | |
| SCHEMBL20625350 | 0.80 | BACE1 (0.46) | GRM5ATMCYP2A6BACE1KCNH2 | |
| SCHEMBL20601899 | 0.79 | GRM5 (0.39) | GRM5 | |
| SCHEMBL20625047 | 0.78 | GRM5 (0.49) | GRM5ATMCYP2A6BACE1KCNH2 | |
| SCHEMBL22025845 | 0.76 | ATM (0.39) | CTSKATMCYP2A6GRIN1GRIN2B | |
| SCHEMBL20601799 | 0.74 | ABL1 (0.44) | CTSKATMGRIN2BNOTUM | |
| SCHEMBL23190452 | 0.73 | BACE1 (0.50) | GRM5BACE1BACE2 | |
| SCHEMBL20603203 | 0.73 | GRM5 (0.47) | GRM5ATMCYP2A6BACE1KCNH2 | |
| SCHEMBL18890284 | 0.72 | IDO1 (0.56) | GRM5ATMNOTUMCYP11B1CYP11B2 | |
| SCHEMBL8274296 | 0.72 | ATM (0.48) | GRM5ATMCYP2A6BACE1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200165225-A1 | BACE1 INHIBITORS FOR TREATMENT OF ALZHEIMER'S DISEASE | NANTBIO, INC. (US) | 2020-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200165225-A1 | BACE1 INHIBITORS FOR TREATMENT OF ALZHEIMER'S DISEASE | BACE1, BACE2, PSEN2 | GRM5 297/4885CTSK 124/4885ATM 2426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.